Public Health News and Research

RSS

States worry over Medicaid expansion; Montana expands kids coverage

State officials continue to worry about additional costs that would stem from a Medicaid expansion. Meanwhile, Montana unveils a plan to expand health insurance for children and Iowa Republicans are touting their own alternative to a federal health care overhaul.

25 Sep 2009

Phase III clinical trial of investigational HIV vaccine regimen complete

Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.

25 Sep 2009

FDA urged to prohibit menthol in tobacco products

Today the American Legacy Foundation(R) (Legacy) urged the Food and Drug Administration (FDA) to prohibit menthol in cigarettes and other flavored tobacco products as one of its first priorities related to the Family Smoking Prevention and Tobacco Control Act (the Act).

25 Sep 2009

African Leaders Malaria Alliance launched at U.N. General Assembly

On the sidelines of the U.N. General Assembly Wednesday, African heads of state formed a 20-member African Leaders Malaria Alliance with the goal of eliminating deaths from malaria by 2015, the Associated Press writes. "With an estimated 500 million annual cases, Africa is the continent most affected by malaria, accounting for 86 percent of all cases and 91 percent of all malaria deaths worldwide, President Jakaya Kikwete of Tanzania said at the alliance's launch," according to the news service (9/24).

25 Sep 2009

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.

25 Sep 2009

Investigational vaccine shows modest potential for protecting against HIV infection

For the first time, scientists say an investigational vaccine has modest potential for protecting people against HIV infection, the Associated Press reports. "The vaccine — a combination of two previously unsuccessful vaccines — cut the risk of becoming infected with HIV by ... 31 percent in the world's largest [HIV] vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok," the news service writes (Marchione/Casey, 9/24).

25 Sep 2009

Diabetes prevalence highest in the Southern and Appalachian states

Diabetes prevalence is highest in the Southern and Appalachian states and lowest in the Midwest and the Northeast of America. Researchers writing in BioMed Central's open access journal Population Health Metrics have used two public data sources to investigate the prevalence of diagnosed and undiagnosed diabetes mellitus at the State level.

25 Sep 2009

Experimental HIV vaccine shows promise

An experimental HIV vaccine raises hope of reducing the risk of infection. Wall Street Journal/Associated Press reports: "For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible."

25 Sep 2009

Only 40% of parents will get their child vaccinated against H1N1?

The latest C.S. Mott Children's Hospital National Poll on Children's Health finds only 40 percent of parents indicate they will get their children vaccinated against H1N1 flu -- while 54 percent of parents indicate they will get their children vaccinated against seasonal flu. Among parents who do not plan to get their children vaccinated against H1N1 flu, 46 percent indicate they are not worried about their children getting H1N1 flu, while 20 percent believe H1N1 flu is not serious.

25 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Customized prosthesis from Custom-fit

Custom-fit is a European funded project, coordinated by Delcam, which has developed a new and cost effective way to manufacture fully customised products, individually designed starting from body geometries and putting together rapid manufacturing, information technologies and material science.

24 Sep 2009

Commitments announced at the Clinton Global Initiative

The second day of the Fifth Annual Meeting of the Clinton Global Initiative (CGI) came to a close with a special session on Northern Ireland, following afternoon plenary and breakout sessions that focused on harnessing innovation for development.

24 Sep 2009

Clinton Global Initiative to raise awareness and funding for NTD control and elimination

At the Clinton Global Initiative today, the Inter-American Development Bank joined with the Global Network for Neglected Tropical Diseases to announce their commitment to mobilize $30 million from the public and private sectors to raise awareness and funding for NTD control and elimination in the Americas, supported by technical assistance from the Pan American Health Organization, regional office of the World Health Organization for the Americas.

24 Sep 2009

Millennium Development Goals strive to reduce malnutrition by half by 2015

Ninety per cent of older persons in rural Bangladesh displayed either overt or risk for malnutrition in a collaborative study presented in a dissertation by Tamanna Ferdous from Uppsala University Sept 22, 2009. The results, which are part of a larger international study, challenge the Millenium Development Goals.

24 Sep 2009

Jean-Pol Tassin honored with the ECNP Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Jean-Pol Tassin as the recipient of the 2009 ECNP Neuropsychopharmacology Award in Basic Science Research in recognition of his pioneering and innovative research into the neurochemical basis of substance addiction.

24 Sep 2009

Regence offers coverage to meet the costs associated with H1N1

To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.

24 Sep 2009

New poll shows bipartisan support to Americans for alcohol and drug addiction treatment

As the debate over health care reform continues on Capitol Hill, a new national poll shows broad, bipartisan support for ensuring that all Americans have access to alcohol and drug addiction treatment.

24 Sep 2009

Research study links cancer to excess body weight

At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study. The proportion of cases of new cancers attributable to a body mass index of 25kg/m2 or more were highest among women and in central European countries such as the Czech Republic, Latvia, Slovenia and Bulgaria.

From The University of Manchester 24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Phase III efficacy trial of two AIDS vaccine candidates shows promise

The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial in Thailand. The prime-boost combination appeared to be about 31% effective at preventing infection with HIV.

24 Sep 2009